The Conversation (0)
Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.
Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) announced that the Japanese Patent Office has granted a patent for the company’s CVac.
As quoted in the press release:
The method of use claims secured in patent number 5192020 entitled “Use of mannose receptor-bearing antigen presenting cells for the manufacture of medicament for eliciting cytotoxic T cell response to antigen” provide for the treatment of patients with dendritic cells that have been pulsed with mannan fusion protein (M-FP) conjugated to an antigen, including but not limited to mucin 1.
Click here to read the full Prima BioMed Ltd (ASX:PRR, NASDAQ:PBMD) press release.
